Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:CPRX NASDAQ:CRNX NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.66+0.1%$21.71$19.69▼$28.35$3.71B0.861.70 million shs1.74 million shsCPRXCatalyst Pharmaceuticals$31.23-0.2%$27.45$19.05▼$32.56$3.82B0.721.77 million shs2.60 million shsCRNXCrinetics Pharmaceuticals$35.55-1.3%$37.65$25.83▼$57.99$3.75B0.281.24 million shs1.93 million shsVERVVerve Therapeutics$11.13$11.13$3.89▼$11.41$992.13M2.234.91 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+2.08%+1.45%-4.59%-11.93%-1.77%CPRXCatalyst Pharmaceuticals-0.10%+0.03%+6.28%+35.57%+27.51%CRNXCrinetics Pharmaceuticals-2.12%-2.91%-5.61%-12.38%+20.39%VERVVerve Therapeutics0.00%0.00%0.00%0.00%+162.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.66+0.1%$21.71$19.69▼$28.35$3.71B0.861.70 million shs1.74 million shsCPRXCatalyst Pharmaceuticals$31.23-0.2%$27.45$19.05▼$32.56$3.82B0.721.77 million shs2.60 million shsCRNXCrinetics Pharmaceuticals$35.55-1.3%$37.65$25.83▼$57.99$3.75B0.281.24 million shs1.93 million shsVERVVerve Therapeutics$11.13$11.13$3.89▼$11.41$992.13M2.234.91 million shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+2.08%+1.45%-4.59%-11.93%-1.77%CPRXCatalyst Pharmaceuticals-0.10%+0.03%+6.28%+35.57%+27.51%CRNXCrinetics Pharmaceuticals-2.12%-2.91%-5.61%-12.38%+20.39%VERVVerve Therapeutics0.00%0.00%0.00%0.00%+162.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.75Moderate Buy$31.6346.01% UpsideCPRXCatalyst Pharmaceuticals 2.56Moderate Buy$32.002.38% UpsideCRNXCrinetics Pharmaceuticals 2.90Moderate Buy$76.13113.43% UpsideVERVVerve Therapeutics 2.00Hold$12.6013.21% UpsideCurrent Analyst Ratings BreakdownLatest VERV, CRNX, CPRX, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026CPRXCatalyst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/18/2026CPRXCatalyst Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/11/2026CRNXCrinetics Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$87.00 ➝ $84.005/8/2026CPRXCatalyst Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/8/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $32.005/8/2026CRNXCrinetics Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$97.00 ➝ $95.005/7/2026CPRXCatalyst Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.005/7/2026CPRXCatalyst Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight5/1/2026ACADACADIA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.46$0.91 per share23.89$7.29 per share2.97CPRXCatalyst Pharmaceuticals$596.96M6.41$2.92 per share10.72$8.27 per share3.78CRNXCrinetics Pharmaceuticals$7.70M488.42N/AN/A$12.15 per share2.94VERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.209.8427.0725.6534.30%9.61%7.07%8/5/2026 (Estimated)CPRXCatalyst Pharmaceuticals$214.33M$1.7417.9610.150.9137.08%35.76%31.31%8/5/2026 (Estimated)CRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/6/2026 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/ALatest VERV, CRNX, CPRX, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48CPRXCatalyst PharmaceuticalsN/A7.106.84CRNXCrinetics PharmaceuticalsN/A18.6018.56VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CPRXCatalyst Pharmaceuticals79.22%CRNXCrinetics Pharmaceuticals98.51%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%CPRXCatalyst Pharmaceuticals10.40%CRNXCrinetics Pharmaceuticals3.80%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableCPRXCatalyst Pharmaceuticals80122.38 million109.65 millionOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableVERV, CRNX, CPRX, and ACAD HeadlinesRecent News About These CompaniesA one-time experimental treatment might control cholesterol for life21 minutes ago | msn.comPharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and moreMay 28 at 9:02 AM | statnews.comSA gene therapy lowered cholesterol in early trial results. It has a Philly backstory.May 28 at 9:02 AM | inquirer.comICan one treatment lower cholesterol and reduce heart attack risk for years?May 26 at 11:59 PM | business-standard.comBCan an injection prevent heart attacks? Eli Lilly’s gene-editing therapy cuts LDL cholesterol by 62%May 26 at 11:59 PM | indianexpress.comILilly says gene editing therapy cut “bad” cholesterol in early-stage trialMay 26 at 11:59 PM | seekingalpha.comSo Far, So Good for PCSK9-Targeting Gene Therapy in HypercholesterolemiaMay 26 at 11:59 PM | medpagetoday.comMLilly is looking for its next act beyond the weight-loss boomMay 26 at 11:59 PM | msn.comEli Lilly-backed gene-editing therapy cuts ‘bad’ cholesterol by up to 62% in early trialMay 26 at 8:28 AM | cnbctv18.comCLilly says gene editing therapy cut bad cholesterol in early-stage trialMay 26 at 8:28 AM | msn.comLilly advances gene therapy, snaps up vaccine makers. It’s looking beyond weight lossMay 26 at 8:28 AM | msn.comLilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitorsMay 25, 2026 | fiercebiotech.comFIn Vivo Base Editing of PCSK9 with VERVE-102 for HypercholesterolemiaMay 25, 2026 | nejm.orgNEli Lilly says Verve’s gene editor lowers cholesterol levels in early studyMay 25, 2026 | statnews.comSThree Biotechs That Are Top Takeover TargetsMay 18, 2026 | 247wallst.comEuropean Biotechs Developing Next-Generation of Cardiometabolic and Precision Cardiology TherapeuticsApril 14, 2026 | pharmtech.comPStudies test whether gene-editing can fix high cholesterolFebruary 17, 2026 | tribtoday.comTStudies test whether gene-editing can fix high cholesterol. For now, take your medicineFebruary 13, 2026 | courant.comCBeyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System DealsFebruary 10, 2026 | genengnews.comGLilly Doubles Down on Eye Diseases, Adding to BD SpreeNovember 10, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVERV, CRNX, CPRX, and ACAD Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.66 +0.03 (+0.14%) Closing price 04:00 PM EasternExtended Trading$21.66 0.00 (-0.02%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Catalyst Pharmaceuticals NASDAQ:CPRX$31.23 -0.06 (-0.19%) Closing price 04:00 PM EasternExtended Trading$31.24 +0.01 (+0.03%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Crinetics Pharmaceuticals NASDAQ:CRNX$35.55 -0.46 (-1.28%) Closing price 04:00 PM EasternExtended Trading$35.55 0.00 (0.00%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Verve Therapeutics NASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
